108 related articles for article (PubMed ID: 11498844)
1. [Progress on the study of related genes in patients with blast crisis of chronic myelocytic leukemia].
Xiong H; Chen X
Zhonghua Xue Ye Xue Za Zhi; 1999 Jan; 20(1):49-51. PubMed ID: 11498844
[No Abstract] [Full Text] [Related]
2. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
[TBL] [Abstract][Full Text] [Related]
3. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
[TBL] [Abstract][Full Text] [Related]
4. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
5. Rearrangement of the BCR/ABL and TCR-beta genes in lymph node blast crisis diagnosed of chronic myeloid leukemia.
Villegas A; González FA
Am J Hematol; 1994 Apr; 45(4):347. PubMed ID: 8178807
[No Abstract] [Full Text] [Related]
6. Author's reply to "Rearrangement of the BCR/ABL and TCR-beta genes in lymph node blast crisis diagnosed of chronic myeloid leukemia".
van der Jagt R; Drouin J; Giulivi A; Huebsch LB; Tittley P
Am J Hematol; 1994 Jul; 46(3):248. PubMed ID: 8192157
[No Abstract] [Full Text] [Related]
7. [Philadelphia chromosome].
Majsterek I; Błasiak J
Postepy Biochem; 2002; 48(3):156-66. PubMed ID: 12625243
[No Abstract] [Full Text] [Related]
8. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases.
Grossmann V; Kohlmann A; Zenger M; Schindela S; Eder C; Weissmann S; Schnittger S; Kern W; Müller MC; Hochhaus A; Haferlach T; Haferlach C
Leukemia; 2011 Mar; 25(3):557-60. PubMed ID: 21274004
[No Abstract] [Full Text] [Related]
9. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
10. Differential display analysis of mRNAs in chronic myelogenous leukaemia.
el-Awady MK; Abdalla NM; Salem AM; Samir S; Nour AM
East Mediterr Health J; 2001; 7(4-5):707-15. PubMed ID: 15332769
[TBL] [Abstract][Full Text] [Related]
11. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
[TBL] [Abstract][Full Text] [Related]
12. The biology of chronic myelogenous leukemia progression: who, what, where, and why?
Radich JP
Hematol Oncol Clin North Am; 2011 Oct; 25(5):967-80, v. PubMed ID: 22054729
[TBL] [Abstract][Full Text] [Related]
13. [Leucemogenesis of chronic myelogenous leukemia].
Mahon FX
Rev Prat; 2005 Oct; 55(15):1642-6. PubMed ID: 16334200
[TBL] [Abstract][Full Text] [Related]
14. Blast crisis accompanied with occurrence of the point-mutational activation of N-ras proto-oncogene and the chromosomal abnormality inv(3q) in chronic myelogenous leukemia presenting thrombocytosis.
Okabe M; Kunieda Y; Saiki I; Shikano T; Kakinuma M; Miyazaki T
Leukemia; 1990 May; 4(5):381-2. PubMed ID: 2201830
[No Abstract] [Full Text] [Related]
15. Influence of BCR/ABL fusion proteins on the course of Ph leukemias.
Telegeev GD; Dubrovska AN; Dybkov MV; Maliuta SS
Acta Biochim Pol; 2004; 51(3):845-9. PubMed ID: 15448745
[TBL] [Abstract][Full Text] [Related]
16. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
17. Chronic myelocytic leukemia with myeloblastoma has higher frequency of ras oncogene mutation.
Tanaka K; Takauchi K; Takechi M; Dohy H; Kamada N
Leuk Res; 1992 Sep; 16(9):947. PubMed ID: 1405725
[No Abstract] [Full Text] [Related]
18. A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase.
Gozzetti A; Tozzuoli D; Crupi R; Gentili S; Raspadori D; Fabbri A; Lauria F
Cancer Genet Cytogenet; 2004 Apr; 150(1):90-1. PubMed ID: 15041233
[No Abstract] [Full Text] [Related]
19. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
[TBL] [Abstract][Full Text] [Related]
20. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.
Moravcová J; Zmeková V; Klamová H; Voglová J; Faber E; Michalová K; Rabasová J; Jarosová M
Leuk Res; 2004 Apr; 28(4):415-9. PubMed ID: 15109543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
